Show simple item record

AuthorIbrahim, Abed Alqader
AuthorNsairat, Hamdi
AuthorAl-Sulaibi, Mazen
AuthorEl-Tanani, Mohamed
AuthorJaber, Areej M.
AuthorLafi, Zainab
AuthorBarakat, Rahmeh
AuthorAbuarqoub, Duaa Azmi
AuthorMahmoud, Ismail Sami
AuthorObare, Sherine O.
AuthorAljabali, Alaa A.A.
AuthorAlkilany, Alaaldin M.
AuthorAlshaer, Walhan
Available date2024-06-23T07:07:34Z
Publication Date2024-04-21
Publication NameExpert Opinion on Drug Delivery
Identifierhttp://dx.doi.org/10.1080/17425247.2024.2343882
CitationIbrahim, A. A., Nsairat, H., Al-Sulaibi, M., El-Tanani, M., Jaber, A. M., Lafi, Z., ... & Alshaer, W. (2024). Doxorubicin conjugates: a practical approach for its cardiotoxicity alleviation. Expert Opinion on Drug Delivery, 21(3), 399-422.
ISSN1742-5247
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85191162839&origin=inward
URIhttp://hdl.handle.net/10576/56164
AbstractIntroduction: Doxorubicin (DOX) emerges as a cornerstone in the arsenal of potent chemotherapeutic agents. Yet, the clinical deployment of DOX is tarnished by its proclivity to induce severe cardiotoxic effects, culminating in heart failure and other consequential morbidities. In response, a panoply of strategies has undergone rigorous exploration over recent decades, all aimed at attenuating DOX’s cardiotoxic impact. The advent of encapsulating DOX within lipidic or polymeric nanocarriers has yielded a dual triumph, augmenting DOX’s therapeutic efficacy while mitigating its deleterious side effects. Areas covered: Recent strides have spotlighted the emergence of DOX conjugates as particularly auspicious avenues for ameliorating DOX-induced cardiotoxicity. These conjugates entail the fusion of DOX through physical or chemical bonds with diminutive natural or synthetic moieties, polymers, biomolecules, and nanoparticles. This spectrum encompasses interventions that impinge upon DOX’s cardiotoxic mechanism, modulate cellular uptake and localization, confer antioxidative properties, or refine cellular targeting. Expert opinion: The endorsement of DOX conjugates as a compelling stratagem to mitigate DOX-induced cardiotoxicity resounds from this exegesis, amplifying safety margins and the therapeutic profile of this venerated chemotherapeutic agent. Within this ambit, DOX conjugates stand as a beacon of promise in the perpetual pursuit of refining chemotherapy-induced cardiac compromise.
Languageen
PublisherTaylor & Francis
SubjectAnthracyclines
bioconjugation
cardiotoxicity
doxorubicin
free radicals
therapeutic index
TitleDoxorubicin conjugates: a practical approach for its cardiotoxicity alleviation
TypeArticle
Pagination399-422
Issue Number3
Volume Number21
ESSN1744-7593
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record